Saturday 17 October 2026
Export HOWL’s income statement to Excel — free account
Werewolf Therapeutics, Inc.
HOWL Healthcare Biotechnology
Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023. In the quarter to June 2026, revenue grew 256.1%, EPS grew 120.0% and free cash flow grew 146.5%, each against the same quarter a year earlier.
0.98
0.02
−2.00%
Follow HOWL
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | 3 | — |
P/E ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
— | — | — | — | 0.00 | 8.29 | 6.91 | — |
Altman Z-Score |
— | — | — | — | (1.92) | (1.29) | (4.83) | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | (0.44) | (1.66) | (8.05) | — |
P/FCF ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
— | — | — | — | — | (2.74) | — | — |
P/Operating CF |
— | — | — | — | (4.98) | (36.07) | (4.50) | — |
P/B ratio |
— | — | — | — | 0.48 | 1.49 | 0.87 | — |
Price to Tangible BV |
— | — | — | — | 0.48 | 1.49 | 0.87 | — |
EV/Sales |
— | — | — | — | 0.00 | 3.19 | (2.24) | — |
EV/EBITDA |
— | — | — | — | 1.05 | 0.00 | 0.29 | — |
EV/Operating CF |
— | — | — | — | 1.42 | (1.95) | 0.37 | — |
EV/FCF |
— | — | — | — | 1.30 | (1.91) | 0.37 | — |
Quick Ratio |
— | 8.76 | 17.52 | 13.27 | 5.68 | 7.00 | 7.31 | 1.58 |
Current Ratio |
— | 8.84 | 17.58 | 13.56 | 5.84 | 7.14 | 7.45 | 1.62 |
Net Debt/EBITDA |
— | 0.81 | 4.08 | 2.87 | 2.13 | 2.63 | 1.18 | 0.97 |
Debt/Assets |
0.00% | 45.40% | 1.93% | 8.14% | 7.86% | 18.68% | 20.56% | 0.00% |
Debt/Equity |
— | (0.40) | (0.04) | 0.10 | 0.10 | 0.29 | 0.36 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.10 | 0.12 | 0.01 | 0.00 |
Operating CF/Net income |
— | 0.52 | 0.66 | 0.21 | 0.75 | 0.87 | 0.80 | 0.99 |
Capex/Depreciation |
— | (10.64) | (3.73) | (2.31) | (2.76) | (0.42) | (0.14) | 0.00 |
Interest Coverage |
— | — | (221.82) | (481.61) | (29.38) | (12.90) | (15.81) | (11.50) |
| — | 47.87% | 74.09% | (400.15%) | (39.12%) | (31.98%) | (76.33%) | (123.88%) | |
| — | (168.17%) | (47.79%) | (146.51%) | (31.70%) | (22.30%) | (46.74%) | (61.96%) | |
ROIC |
— | 0.00% | 0.00% | (317.97%) | (623.18%) | (261.32%) | 0.00% | 0.00% |
Return on Tangible Assets |
— | (112.11%) | (31.96%) | (132.75%) | (42.98%) | (29.44%) | (67.67%) | (224.22%) |
Average Days of Receivables |
— | — | — | — | 154.18 | 24.71 | 0.00 | — |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 327.79% | 209.48% | 2,993.85% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 113.99% | 93.62% | 1,010.34% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 45.12% | 40.15% | 468.22% | 0.00% |
Graham Net Nets |
— | — | — | — | 1.73 | 0.45 | 0.93 | — |
Graham Number |
— | — | — | — | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
— | — | — | — | (91.71%) | (22.41%) | (110.14%) | — |
Free Cash Flow Yield |
— | — | — | — | (74.71%) | (20.18%) | (88.01%) | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.57 | 0.56 | 0.04 | 0.00 |
Operating CF per Share |
— | (14.91) | (18.53) | (2.32) | (1.41) | (0.91) | (1.30) | (1.31) |
Capex per Share |
— | (0.42) | (0.56) | (0.03) | (0.13) | (0.02) | (0.01) | 0.00 |
Free Cash Flow per Share |
— | (15.32) | (19.09) | (2.35) | (1.53) | (0.94) | (1.30) | (1.31) |
Cash per Share |
— | 27.96 | 92.11 | 8.54 | 4.48 | 3.77 | 2.56 | 1.24 |
Shareholders Equity per Share |
— | (37.97) | (51.60) | 8.28 | 4.24 | 3.12 | 1.69 | 0.54 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (37.97) | (51.60) | 8.28 | 4.24 | 3.12 | 1.69 | 0.54 |
Free Cash Flow |
— | (9.81) | (19.18) | (43.37) | (44.21) | (33.38) | (56.44) | (60.29) |
Working Capital |
— | 16.02 | 87.63 | 149.19 | 116.21 | 118.99 | 97.89 | 22.44 |
Capital Expenditures |
— | (0.27) | (0.56) | (0.50) | (3.61) | (0.77) | (0.25) | — |
Net Current Asset Value |
— | (27.92) | (55.35) | 134.61 | 102.29 | 74.91 | 59.53 | 14.00 |
EV/EBIT |
— | — | — | — | 1.03 | 0.00 | 0.28 | — |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.22 | 0.04 | 0.13 | — |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.10 | 0.23 | 0.07 | 0.15 | 0.23 | 0.29 | 0.35 |
Cash ROIC |
— | (285.53%) | (45.06%) | (13.35%) | (16.73%) | (11.99%) | (26.82%) | (73.66%) |
Accounts Receivable Turnover |
— | — | — | — | 0.00 | 4.82 | 0.00 | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | — | — | 4.14 | — | — |
Average Payables |
— | 0.83 | 0.83 | 1.53 | 1.63 | 1.28 | 2.19 | 1.89 |
Average Assets |
— | 10.84 | 59.04 | 137.82 | 169.75 | 167.54 | 150.88 | 98.16 |
Average Common Equity |
— | (38.08) | (38.08) | 50.46 | 137.56 | 116.86 | 92.38 | 49.10 |
Columns are period end dates